Neuhann, J. M. Et Al. 2023. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1). Vaccine , vol.41, no.48 , 7166-7175.

Neuhann, J. M., Stemler, J., Carcas, A. J., Frías-Iniesta, J., AKOVA, M., Bethe, U., ... Heringer, S.(2023). Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1). Vaccine , vol.41, no.48, 7166-7175.

Neuhann, Julia Et Al. "Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)," Vaccine , vol.41, no.48, 7166-7175, 2023

Neuhann, Julia M. Et Al. "Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)." Vaccine , vol.41, no.48, pp.7166-7175, 2023

Neuhann, J. M. Et Al. (2023) . "Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)." Vaccine , vol.41, no.48, pp.7166-7175.

@article{article, author={Julia M. Neuhann Et Al. }, title={Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)}, journal={Vaccine}, year=2023, pages={7166-7175} }